Abstract:Purpose
The aim of this study was to investigate the effect of product dose in autologous chondrocyte implantation (ACI) for the treatment of full‐thickness cartilage defects of the knee and to assess its influence on clinical and morphological mid‐term outcome.
Methods
Seventy‐five patients were included in this single‐blind, randomised, prospective, controlled clinical trial. Patients were assigned randomly to three different dose groups [low (3–7 spheroids/cm2), medium (10–30 spheroids/cm2), or high (40–70 … Show more
“…The literature search yielded 34 publications in PubMed and 70 in Web of Science. After removing 29 duplicates and screening the titles and abstracts, the full texts of 21 publications were screened, after which 18 [7,[10][11][12][13][14][15][17][18][19][20][21][22][23][24][25][26][27] were included and 3 [28][29][30] were excluded due to the use of xenogeneic materials [28] or antibiotics [29] in the cell culture, or the spheroids were formed by pelleting cells with centrifugation [30]. Two additional articles [16,31] were identified from citations (Figure 2).…”
Section: Resultsmentioning
confidence: 99%
“…The phase II clinical trial was a prospective, single-blinded, multicenter, doseconfirmation study in which the safety and efficacy of three different doses of Spherox for the treatment of cartilage defects in the knee were investigated (ClinicalTrials.gov identifier: NCT01225575, EudraCt No. 2009-016816-20) [10][11][12]. The primary outcome was the increase in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS) at 12 months follow-up, which was improved from mean 57.0 ± 15.2 to 73.4 ± 17.3 (Table 3) [10].…”
Autologous chondrocyte implantation (ACI) is a cell therapy for the treatment of focal cartilage defects. The ACI product that is currently approved for use in the European Union (EU) consists of spheroids of autologous matrix-associated chondrocytes. These spheroids are spherical aggregates of ex vivo expanded human autologous chondrocytes and their self-synthesized extracellular matrix. The aim is to provide an overview of the preclinical and nonclinical studies that have been performed to ensure reproducible quality, safety, and efficacy of the cell therapy, and to evaluate the clinical data on ACI with spheroids. A systematic review was performed to include all English publications on self-aggregated spheroids of chondrocytes cultured in autologous serum without other supplements. A total of 20 publications were included, 7 pre- and nonclinical and 13 clinical research publications. The pre- and nonclinical research publications describe the development from concept to in vivo efficacy and quality- and safety-related aspects such as biodistribution, tumorigenicity, genetic stability, and potency. The evaluation of clinical research shows short- to mid-term safety and efficacy for the ACI with spheroid-based treatment of cartilage defects in both randomized clinical trials with selected patients, as well as in routine treatment providing real-world data in more complex patients.
“…The literature search yielded 34 publications in PubMed and 70 in Web of Science. After removing 29 duplicates and screening the titles and abstracts, the full texts of 21 publications were screened, after which 18 [7,[10][11][12][13][14][15][17][18][19][20][21][22][23][24][25][26][27] were included and 3 [28][29][30] were excluded due to the use of xenogeneic materials [28] or antibiotics [29] in the cell culture, or the spheroids were formed by pelleting cells with centrifugation [30]. Two additional articles [16,31] were identified from citations (Figure 2).…”
Section: Resultsmentioning
confidence: 99%
“…The phase II clinical trial was a prospective, single-blinded, multicenter, doseconfirmation study in which the safety and efficacy of three different doses of Spherox for the treatment of cartilage defects in the knee were investigated (ClinicalTrials.gov identifier: NCT01225575, EudraCt No. 2009-016816-20) [10][11][12]. The primary outcome was the increase in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS) at 12 months follow-up, which was improved from mean 57.0 ± 15.2 to 73.4 ± 17.3 (Table 3) [10].…”
Autologous chondrocyte implantation (ACI) is a cell therapy for the treatment of focal cartilage defects. The ACI product that is currently approved for use in the European Union (EU) consists of spheroids of autologous matrix-associated chondrocytes. These spheroids are spherical aggregates of ex vivo expanded human autologous chondrocytes and their self-synthesized extracellular matrix. The aim is to provide an overview of the preclinical and nonclinical studies that have been performed to ensure reproducible quality, safety, and efficacy of the cell therapy, and to evaluate the clinical data on ACI with spheroids. A systematic review was performed to include all English publications on self-aggregated spheroids of chondrocytes cultured in autologous serum without other supplements. A total of 20 publications were included, 7 pre- and nonclinical and 13 clinical research publications. The pre- and nonclinical research publications describe the development from concept to in vivo efficacy and quality- and safety-related aspects such as biodistribution, tumorigenicity, genetic stability, and potency. The evaluation of clinical research shows short- to mid-term safety and efficacy for the ACI with spheroid-based treatment of cartilage defects in both randomized clinical trials with selected patients, as well as in routine treatment providing real-world data in more complex patients.
“…The search included 10 studies 11 , 12 , 14 , 15 , 19 , 20 , 29 , 33 , 34 , 36 that fulfilled the inclusion criteria: 2 randomized controlled trials, 15 , 19 7 case series, 11 , 12 , 19 , 20 , 33 , 34 , 36 and 1 cohort study. 14 Of the 10 studies, 6 studies addressed ACT3D of articular cartilage defects in the knee joint, 11 , 14 , 15 , 29 , 33 , 34 and 4 publications investigated the outcome of ACT3D therapy in affected hip joints. 12 , 19 , 20 , 36 The mean defect size of the treated lesions ranged from 2 to 6 cm 2 .…”
Section: Resultsmentioning
confidence: 99%
“…33,34 ACT3D further proved to be a suitable therapy for children and adolescents with chondral defects. 14 In 2020, Niemeyer et al 29 published the 4-year outcomes of their European Medicines Agency (EMA)-driven, prospective, phase II study addressing the dose-dependent safety and efficacy of Chondrosphere. The study did not reveal any statistically significant differences between different concentrations of spheroids in the dose range of 10 to 70 spheroids/cm 2 .…”
Section: Act3d In the Knee Jointmentioning
confidence: 99%
“…Hoburg (2019) adults 14 92.9 ± 7.9 (n ¼ 30) Siebold (2018) 34 77.7 ± 14.6 (n ¼ 30) Siebold (2016) 33 79.0 ± 18.0 (n ¼ 31) Fickert (2012) 11 82. 34 84.2 ± 5.6 (n ¼ 30) Siebold (2016) 33 63.0 ± 18.8 (n ¼ 31) Fickert (2012) 11 64.0 (n ¼ 37) Weighted average 73.5 (n ¼ 147) KOOS (overall) Hoburg (2020) 15,28 83.2 ± 14.9 (n ¼ 48) Niemeyer (2020) 5,27,29 77. 34 used a maximum MOCART score of 85 rather than 100; to compare their results with those of the other studies, we used the percentage instead of the absolute value.…”
Background: A 3-dimensional, scaffold-free, and completely autologous form of chondrocyte transplantation (ACT3D) has been developed and applied in clinical practice in the past decade to overcome disadvantages of previous-generation procedures. Purpose: To document and analyze the available literature on the results of ACT3D in the treatment of articular chondral lesions in the knee and hip joints. Study Design: Systematic review; Level of evidence, 4. Methods: All studies published in English addressing ACT3D were identified and included those that fulfilled the following criteria: (1) level 1 through 4 evidence, (2) measures of radiological or functional/clinical outcome, and (3) outcome related to cartilage lesions of the knee and hip joints. Results: A total of 10 studies were selected: 2 randomized controlled trials, 1 cohort study, and 7 case series. The studies revealed significant increases in patients’ subjective quality of life, satisfaction, pain reduction, and improvement in joint function at short- to medium-term follow-up. Magnetic resonance imaging-assisted examination and second-look arthroscopy showed a hyaline-like repair tissue with a high degree of defect filling and integration. Conclusion: ACT3D shows promising results in the therapy of articular cartilage defects in the knee as well as in the hip, but well-designed, long-term studies are lacking. ACT3D might have relevant advantages over common matrix-associated autologous chondrocyte transplantation products, but systematic evaluation and randomized controlled studies are crucial to verify the potential of this tissue-engineered approach.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.